Tata Chemicals Ltd (BOM:500770) reports robust standalone performance with significant revenue and profit growth, despite facing global market pressures and geopolitical risks.

Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete - Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit ...